Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2019 | Nab-paclitaxel and gemcitabine in soft tissue sarcoma: trial update

Speaking from the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain, Yannis Metaxas, MD, Cantonal Hospital Grison, Chur, Switzerland, discusses the results from the phase I part of the phase I/II SAKK 57/16 trial (NCT03524898). This study investigated nab-paclitaxel and gemcitabine in soft tissue sarcoma.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.